Congenital disorder of glycosylation type II
MONDO:0005501A congenital disorder of glycosylation that involves malfunctioning trimming/processing of the protein-bound oligosaccharide chain.
Also known as: congenital disorder of glycosylation type II, congenital disorders of glycosylation, type II, B4GALT1-CDG, B4GALT1-CDG (CDG-2d), MGAT2-CDG, MGAT2-CDG (CDG-2a), MOGS-CDG, MOGS-CDG (CDG-2b)
3 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Hope for rare immune disease: new drug enters final testing
Disease control Recruiting nowThis study tests an experimental drug called AVTX-803 in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic condition that weakens the immune system and leads to frequent infections. The trial will compare the drug against a period without treatment to see…
Phase: PHASE3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental sugar therapy tested for ultra-rare immune disorder
Disease control Recruiting nowThis phase 3 study is testing the long-term safety and effectiveness of AVTX-803, a form of L-fucose, in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic disorder that weakens the immune system. Only 2 participants who completed a previous study are enro…
Phase: PHASE3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC